9 results about "Death Receptors" patented technology

Disclosed herein, in some aspects, are methods of treating autoimmune diseases or conditions using TCR targeting molecules or cells expressing TCR targeting molecules. TCR targeting molecules can comprise a moiety that binds to a TCR variable beta chain (TCRBV) or a TCR variable alpha chain (TCRAV). TCR targeting molecules can further comprise one, two or all of: (ii) an immune cell engager; (iii) a cytokine inhibitor molecule; (iv) a cytotoxic agent; and / or (v) a death receptor signal enhancer. Additionally, disclosed herein, in some aspects, are nucleic acids encoding the same, and methods of producing the aforesaid molecules.

The present invention relates to a multispecific antibody comprising a FAPα-binding region comprising at least a first heavy chain variable region and a first light chain variable region, and a DR4-binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibody, and uses of the antibody in therapeutic and diagnostic procedures, particularly in cancer treatment.

An immune related adverse event marker and a kit. The immune related adverse event marker comprises CD183. The immune related adverse event marker can effectively predict immune related adverse events caused by programmed death receptor 1 antibody / programmed death-ligand antibody therapy, thereby facilitating intervention and treatment of immune related adverse events.

In some embodiments, methods for treating autoimmune diseases or conditions using TCR-targeting molecules or cells expressing TCR-targeting molecules are disclosed herein. TCR-targeting molecules may include a moiety that binds to a variable TCR beta chain (TCRBV) or a variable TCR alpha chain (TCRAV). TCR-targeting molecules may further include one, two, or all of the following: (ii) immune cell engagers, (iii) cytokine inhibitors, (iv) cytotoxic agents, and / or (v) death receptor signal enhancers. Furthermore, in some embodiments herein, encoding nucleic acids and methods for producing the aforementioned molecules are disclosed herein.

The invention provides a multifunctional molecule combined with T cells and application of the multifunctional molecule to treatment of autoimmune diseases. A multifunctional molecule comprising i) an antigen binding domain that binds to a TCR variable beta chain (TCRBV) antigen; and one, two or all of (ii) an immune cell adaptor (e.g., selected from an NK cell adaptor, a T cell adaptor, a B cell adaptor, a dendritic cell adaptor or a macrophage adaptor); (iii) a cytokine molecule or a cytokine inhibitor molecule; and / or (iv) a death receptor signal enhancer. In addition, nucleic acids encoding the multifunctional molecules, methods of producing the molecules, and methods of treating autoimmune diseases using the molecules are also disclosed.

The present disclosure provides modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising chimeric antigen receptors (CARs) specific for Death receptor-5 (DR5), and compositions and methods related thereto.

Disclosed herein, in some aspects, are methods of treating autoimmune diseases or conditions using TCR targeting molecules or cells expressing TCR targeting molecules. TCR targeting molecules can comprise a moiety that binds to a TCR variable beta chain (TCRBV) or a TCR variable alpha chain (TCRAV). TCR targeting molecules can further comprise one, two or all of: (ii) an immune cell engager; (iii) a cytokine inhibitor molecule; (iv) a cytotoxic agent; and / or (v) a death receptor signal enhancer. Additionally, disclosed herein, in some aspects, are nucleic acids encoding the same, and methods of producing the aforesaid molecules.

The application belongs to the field of biological medicine, and relates to a combination of a DR5 agonist and an immune checkpoint inhibitor for preparing a drug for treating tumors. The application provides application of a death receptor 5 agonist in preparation of an anti-tumor drug in combination with one or more of a PD-1 inhibitor, a PD-L1 inhibitor, a NKG2A inhibitor and a chemotherapeutic drug. It is found that the DR5 agonistic antibody can further increase the single drug efficacy of the immune checkpoint inhibitor. On this basis, the DR5 agonistic antibody and the immune checkpoint inhibitor can also be combined with chemotherapy to further improve the effect of immunotherapy. The application can further promote the development of immunotherapy in the field of tumor treatment, optimize the tumor treatment pattern, and is expected to be applied in the clinic to improve the tumor treatment effect and the survival rate of patients.

This disclosure relates to compositions and methods for treating cancer with membrane-bound TRAILR2 (DR5) agonist armored T cells.